260 related articles for article (PubMed ID: 30599233)
1. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent.
Liu J; Chi D; Pan S; Zhao L; Wang X; Wang D; Wang Y
Int J Pharm; 2019 Feb; 557():264-272. PubMed ID: 30599233
[TBL] [Abstract][Full Text] [Related]
2. Palmitoyl ascorbate and doxorubicin co-encapsulated liposome for synergistic anticancer therapy.
Yang Y; Lu X; Liu Q; Dai Y; Zhu X; Wen Y; Xu J; Lu Y; Zhao D; Chen X; Li N
Eur J Pharm Sci; 2017 Jul; 105():219-229. PubMed ID: 28526602
[TBL] [Abstract][Full Text] [Related]
3. The influence of trapping agents on the antitumor efficacy of irinotecan liposomes: head-to-head comparison of ammonium sulfate, sulfobutylether-β-cyclodextrin and sucrose octasulfate.
Yang W; Yang Z; Fu J; Guo M; Sun B; Wei W; Liu D; Liu H
Biomater Sci; 2018 Dec; 7(1):419-428. PubMed ID: 30500018
[TBL] [Abstract][Full Text] [Related]
4. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
[TBL] [Abstract][Full Text] [Related]
5. Derma roller® microneedles-mediated transdermal delivery of doxorubicin and celecoxib co-loaded liposomes for enhancing the anticancer effect.
Ahmed KS; Shan X; Mao J; Qiu L; Chen J
Mater Sci Eng C Mater Biol Appl; 2019 Jun; 99():1448-1458. PubMed ID: 30889679
[TBL] [Abstract][Full Text] [Related]
6. Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft.
Shaikh IM; Tan KB; Chaudhury A; Liu Y; Tan BJ; Tan BM; Chiu GN
J Control Release; 2013 Dec; 172(3):852-61. PubMed ID: 24459693
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.
Riviere K; Kieler-Ferguson HM; Jerger K; Szoka FC
J Control Release; 2011 Aug; 153(3):288-96. PubMed ID: 21600250
[TBL] [Abstract][Full Text] [Related]
8. Dimeric Artesunate-Phosphatidylcholine-Based Liposomes for Irinotecan Delivery as a Combination Therapy Approach.
He W; Du Y; Wang T; Wang J; Cheng L; Li X
Mol Pharm; 2021 Oct; 18(10):3862-3870. PubMed ID: 34470216
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
[TBL] [Abstract][Full Text] [Related]
10. Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy.
Zhang B; Wang T; Yang S; Xiao Y; Song Y; Zhang N; Garg S
J Control Release; 2016 Sep; 238():10-21. PubMed ID: 27432750
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
12. DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy.
Camacho KM; Menegatti S; Vogus DR; Pusuluri A; Fuchs Z; Jarvis M; Zakrewsky M; Evans MA; Chen R; Mitragotri S
J Control Release; 2016 May; 229():154-162. PubMed ID: 27034194
[TBL] [Abstract][Full Text] [Related]
13. Co-assembly of doxorubicin and curcumin targeted micelles for synergistic delivery and improving anti-tumor efficacy.
Ma W; Guo Q; Li Y; Wang X; Wang J; Tu P
Eur J Pharm Biopharm; 2017 Mar; 112():209-223. PubMed ID: 27913127
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity.
Lages EB; Fernandes RS; Silva JO; de Souza ÂM; Cassali GD; de Barros ALB; Miranda Ferreira LA
Biomed Pharmacother; 2020 Dec; 132():110876. PubMed ID: 33113428
[TBL] [Abstract][Full Text] [Related]
15. Dual-effect liposomes encapsulated with doxorubicin and chlorin e6 augment the therapeutic effect of tumor treatment.
Peng PC; Hong RL; Tsai YJ; Li PT; Tsai T; Chen CT
Lasers Surg Med; 2015 Jan; 47(1):77-87. PubMed ID: 25559348
[TBL] [Abstract][Full Text] [Related]
16. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
[TBL] [Abstract][Full Text] [Related]
17. Cargo-Free Nanomedicine with pH Sensitivity for Codelivery of DOX Conjugated Prodrug with SN38 To Synergistically Eradicate Breast Cancer Stem Cells.
Sun N; Zhao C; Cheng R; Liu Z; Li X; Lu A; Tian Z; Yang Z
Mol Pharm; 2018 Aug; 15(8):3343-3355. PubMed ID: 29923726
[TBL] [Abstract][Full Text] [Related]
18. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation.
Li Q; Lv S; Tang Z; Liu M; Zhang D; Yang Y; Chen X
Int J Pharm; 2014 Aug; 471(1-2):412-20. PubMed ID: 24905776
[TBL] [Abstract][Full Text] [Related]
19. Development of Long-Circulating and Fusogenic Liposomes Co-encapsulating Paclitaxel and Doxorubicin in Synergistic Ratio for the Treatment of Breast Cancer.
Roque MC; Franco MS; Vilela JMC; Andrade MS; de Barros ALB; Leite EA; Oliveira MC
Curr Drug Deliv; 2019; 16(9):829-838. PubMed ID: 31622204
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of doxorubicin and imatinib by pH sensitive cleavable PEGylated nanoliposomes with folate-mediated targeting to overcome multidrug resistance.
Chen Y; Cheng Y; Zhao P; Zhang S; Li M; He C; Zhang X; Yang T; Yan R; Ye P; Ma X; Xiang G
Int J Pharm; 2018 May; 542(1-2):266-279. PubMed ID: 29551747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
